SCIEX and the National University of Singapore Faculty of Science Sign a Memorandum of Understanding to Accelerate Cancer Biomarker Discovery in Southeast Asia

2015年05月18日 PM08:05



SCIEX, a global leader in life science analytical technologies, and the Protein and Proteomics Centre (PPC) under the Department of Biological Sciences of the National University of Singapore’s (NUS) Faculty of Science, announced they have signed a Memorandum of Understanding (MOU) to promote joint research and development activities in oncology biomarker discovery and development. The collaboration will pave the way for accelerated cancer detection and screening. PPC and SCIEX will work closely with academic and industrial partners in biomedical research.

Proteomics is a large scale high-throughput study of the structure, functions and interactions of proteins, and is used in the research of diseases, treatment, and drug discovery. Cancer protein biomarkers may be physical, chemical, or biological parameters that indicate presence of cancer, or its status or progression. The PPC is a multi-user facility focusing on advanced research in proteins with an emphasis on mass spectrometry. Areas of expertise include biomarker discovery, proteomics, quantitative proteomics, and structural mass spectrometry (Amide Hydrogen/Deuterium Exchange MS and Ion Mobility MS).

Under the MOU, SCIEX and PPC’s areas of cooperation will include facilitating workshops on qualitative and quantitative proteomics to educate the regional research community on alternative methods for proteomics. SCIEX and PPC researchers will also collaborate to develop mass spectrometry approaches for protein and metabolite profiling of zebrafish serum.

The zebrafish is a widely used model organism for biomedical research due to similarity of their genetic makeup with humans. In particular, various zebrafish cancer models have been developed to facilitate cancer research.

Subsequent approaches and technologies developed by researchers will be applied to discover biomarkers of cancer progression, study the mechanisms and pharmacokinetics/pharmacodynamics of anti-cancer drugs, and uncover biomarkers for environmental monitoring.

In order to conduct the research, PPC has in possession three mass spectrometers from SCIEX, including the QTRAP® 6500 System given by SCIEX on consignment, TripleTOF® 5600 System, and 4800 Plus MALDI TOF/TOF™ Analyzer, as well as the SWATH™ 2.0 Acquisition software. The instruments are particularly designed for proteomics identification and quantitation and the SWATH Acquisition module enables the quantification of thousands of protein biomarkers across large sample sets with a level of data completeness and precision that brings next-generation proteomics to researchers.

“With Asia’s growing affluence and ageing population, incidences of lifestyle diseases such as cancers are also on the rise in the region. As a research facility focused on advanced research in proteins, the PPC’s expertise in areas such as oncology biomarkers serves to inform future innovation in cancer research. We are pleased to embark on this collaboration with SCIEX, whose technological expertise in mass spectrometry will further enhance and supplement our study in proteomics and spur our work in cancer biomarker discovery,” said Professor Paul Matsudaira, Head of Department, Department of Biological Sciences, NUS.

“It is our honour that SCIEX is one of the trusted industrial partners of PPC to advance cancer biomarker research in Singapore. The partnership between the two entities has been strong over the years. With the MOU in place, it will undoubtedly bring the relationship and cancer biomarker discovery to the next level.” commented Johnson Ho, Vice President, Sales and Support, Asia Pacific. “We are delighted to announce that the proteomics centre will be open to regional researchers carrying out research in the same field.” added Ho.

“SCIEX has a strong base in Singapore, with our state-of-the-art global manufacturing centre for Mass Spectrometry and Liquid Chromatography, and our Asia Pacific customer support and training centre. In 2013, we also established an R&D centre in Singapore to focus on innovations for our high growth market customers,” said Jean-Paul Mangeolle, President of SCIEX. “Our collaboration with PPC is another milestone that reflects our dedication to enabling Singapore-based researchers to find answers that will lead to new discoveries around disease pathways and drug development.”


SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company’s global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.

With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit www.sciex.com.

SCIEX social: Twitter: @SCIEXnews, LinkedIn and Facebook.

For research use only. Not for use in diagnostic procedures. RUO-MKT-12-2229

AB Sciex is operating as SCIEX.

© 2015 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license.

About National University of Singapore (NUS)

A leading global university centred in Asia, the National University of Singapore (NUS) is Singapore’s flagship university, which offers a global approach to education and research, with a focus on Asian perspectives and expertise.

NUS has 16 faculties and schools across three campuses. Its transformative education includes a broad-based curriculum underscored by multi-disciplinary courses and cross-faculty enrichment. Over 37,000 students from 100 countries enrich the community with their diverse social and cultural perspectives.

NUS has three Research Centres of Excellence (RCE) and 26 university-level research institutes and centres. It is also a partner in Singapore’s fifth RCE. NUS shares a close affiliation with 16 national-level research institutes and centres. Research activities are strategic and robust, and NUS is well-known for its research strengths in engineering, life sciences and biomedicine, social sciences and natural sciences. It also strives to create a supportive and innovative environment to promote creative enterprise within its community.

This year, NUS celebrates its 110th year of founding together with Singapore’s 50th year of independence. As the island’s first higher education institution established by the local community, NUS prides itself in nurturing generations of leaders and luminaries in Singapore and Asia.

For more information on NUS, please visit www.nus.edu.sg. Details on NUS’ 110th Anniversary celebrations are available at nus110.sg.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150518005278/en/


EASTWEST Public Relations for SCIEX
Melinda Ilagan/Grace Yu, +65
6222 0306

Related Posts Plugin for WordPress, Blogger...


  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease